PLX 200

Drug Profile

PLX 200

Alternative Names: PLX200

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polaryx Therapeutics
  • Class Small molecules
  • Mechanism of Action Tripeptidyl-peptidase 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuronal ceroid lipofuscinosis

Most Recent Events

  • 08 Aug 2017 PLX 200 receives Orphan Drug status for Neuronal ceroid lipofuscinosis in USA
  • 08 May 2017 PLX 200 is available for licensing as of 08 May 2017. http://www.polaryx.com/index.html (Polaryx Therapeutics pipeline, May 2017)
  • 08 May 2017 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (PO) before May 2017 (Polaryx Therapeutics pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top